title: Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine.
abstract: Sera from individuals across the USA and Peace Corps Volunteers (PCV) were assayed for neutralizing antibody to human diploid cell rabies vaccine (HDCV). A pairwise comparison between intramuscular (i.m.) and intradermal (i.d.) administration, PCV and non-PCV, revealed statistically significant differences between i.m. and i.d. for PCV and non-PCV, and between PCV and non-PCV for i.d. and i.m. administration. Survival analysis and frequency tables employing chi 2 tests determined that the percentage probability of maintaining an adequate titre from 1.5-2.0 years after primary vaccination was 99% in non-PCV i.m., 93% in non-PCV i.d., 88% in PCV i.m., and 64% in PCV i.d.
authors.affiliation: Department of Veterinary Diagnosis, Kansas State University, Manhattan 66506.
authors.forename: D J
authors.initials: DJ
authors.lastname: Briggs
authors.forename: J R
authors.initials: JR
authors.lastname: Schwenke
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology*; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D011819:Rabies Vaccines